BioStem Technologies, Inc.

As of September 30, 2025, BioStem Technologies, Inc. carries a market capitalization of 78.63M, placing it among publicly traded companies globally. Its enterprise value stands at 54.86M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

BioStem Technologies, Inc.'s next confirmed earnings release is scheduled for August 12, 2026.

As of September 30, 2025, BioStem Technologies, Inc. has 16.77M shares outstanding.

As of September 30, 2025, BioStem Technologies, Inc. trades at a trailing price-to-earnings ratio of 3.36. The price-to-sales ratio is 0.54, and the price-to-book ratio stands at 1.57.

As of September 30, 2025, BioStem Technologies, Inc. trades at an EV/EBITDA multiple of 2.79 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 0.38 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 2.84 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 54.86M versus a market cap of 78.63M, with the gap driven by net debt and cash on the balance sheet.

As of September 30, 2025, BioStem Technologies, Inc. maintains a current ratio of 4.31, meaning it holds 4.3x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 6.77, indicating elevated leverage, while an interest coverage ratio of 96.18 demonstrates strong ability to service its debt obligations.

These figures cover the twelve months ended September 30, 2025. Return on assets (ROA) stands at 70.19, measuring how efficiently the asset base is converted into earnings. The company generates approximately 5.95M in revenue per employee across its workforce of 24.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 6.19 indicates how many times BioStem Technologies, Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended September 30, 2025, BioStem Technologies, Inc. recorded an income tax benefit of -3.89M rather than an expense, typically from losses, carryforwards, or the release of a tax provision. Taxes are levied on pretax income of 19.22M, leaving 23.11M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on August 6, 2026, BioStem Technologies, Inc.'s stock has declined approximately 62.29% over the past 52 weeks. The 50-day moving average sits at 3.71, while the 200-day moving average is 4.55.

Over the twelve months ended September 30, 2025, BioStem Technologies, Inc. generated 142.72M in revenue and converted that into 23.11M in net income, yielding earnings per share of 1.02. EBITDA reached 19.64M, while operating income came in at 19.33M.

As of September 30, 2025, BioStem Technologies, Inc. holds 27.16M in cash and equivalents against 3.39M in total debt, resulting in a net debt position of -24.16M. Total book value stands at 50.02M, with working capital of 40.47M providing operational flexibility.

These figures cover the twelve months ended September 30, 2025.

Over the twelve months ended September 30, 2025, BioStem Technologies, Inc. posted a gross margin of 93.23, reflecting its pricing power and cost economics. The operating margin of 13.55 and net profit margin of 16.19 provide insight into operational efficiency.

BioStem Technologies, Inc.'s most recent stock split took place on January 29, 2015 with a 400:1 split ratio.

As of September 30, 2025, BioStem Technologies, Inc. has an Altman Z-Score of 7.72, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.